{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:20:29Z","timestamp":1794007229936,"version":"4.8.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"St. Josef's Hospital Fund, Reykjavik, Iceland","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Landspitali University Hospital Research Fund, Reykjavik, Iceland","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Icelandic Research Fund of the Icelandic Centre for Research, Reykjavik, Iceland","award":["163172-051"],"award-info":[{"award-number":["163172-051"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuroinflammation has gained increasing attention as a potential contributing factor in the onset and progression of Alzheimer\u2019s disease (AD). The objective of this study was to examine the association of selected cerebrospinal fluid (CSF) inflammatory and neuronal degeneration markers with signature CSF AD profile and cognitive functions among subjects at the symptomatic pre- and early dementia stages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this cross-sectional study, 52 subjects were selected from an Icelandic memory clinic cohort. Subjects were classified as having AD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928, age\u2009=\u200970, 39% female, Mini-Mental State Examination [MMSE]\u2009=\u200927) or non-AD (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200924, age\u2009=\u200967, 33% female, MMSE\u2009=\u200928) profile based on the ratio between CSF total-tau (T-tau) and amyloid-\u03b2\n                      <jats:sub>1\u201342<\/jats:sub>\n                      (A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ) values (cut-off point chosen as 0.52). Novel CSF biomarkers included neurofilament light (NFL), YKL-40, S100 calcium-binding protein B (S100B) and glial fibrillary acidic protein (GFAP), measured with enzyme-linked immunosorbent assays (ELISAs). Subjects underwent neuropsychological assessment for evaluation of different cognitive domains, including verbal episodic memory, non-verbal episodic memory, language, processing speed, and executive functions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Accuracy coefficient for distinguishing between the two CSF profiles was calculated for each CSF marker and test. Novel CSF markers performed poorly (area under curve [AUC] coefficients ranging from 0.61 to 0.64) compared to tests reflecting verbal episodic memory, which all performed fair (AUC\u2009&gt;\u200970). LASSO regression with a stability approach was applied for the selection of CSF markers and demographic variables predicting performance on each cognitive domain, both among all subjects and only those with a CSF AD profile. Relationships between CSF markers and cognitive domains, where the CSF marker reached stability selection criteria of &gt;\u200975%, were visualized with scatter plots. Before calculations of corresponding Pearson\u2019s correlations coefficients, composite scores for cognitive domains were adjusted for age and education. GFAP correlated with executive functions (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.37,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01) overall, while GFAP correlated with processing speed (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.68,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and NFL with verbal episodic memory (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u2009\u2212\u20090.43,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02) among subjects with a CSF AD profile.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The novel CSF markers NFL and GFAP show potential as markers for cognitive decline among individuals with core AD pathology at the symptomatic pre- and early stages of dementia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-020-00657-8","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T01:42:16Z","timestamp":1596591736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Association of glial and neuronal degeneration markers with Alzheimer\u2019s disease cerebrospinal fluid profile and cognitive functions"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2723-2242","authenticated-orcid":false,"given":"Unnur D.","family":"Teitsdottir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Jonsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun H.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taher","family":"Darreh-Shori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Snaedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petur H.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"issue":"4","key":"657_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"657_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804.","journal-title":"N Engl J Med"},{"issue":"2","key":"657_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrn2967","volume":"12","author":"LM Ittner","year":"2011","unstructured":"Ittner LM, Gotz J. Amyloid-beta and tau--a toxic pas de deux in Alzheimer\u2019s disease. Nat Rev Neurosci. 2011;12(2):65\u201372.","journal-title":"Nat Rev Neurosci"},{"key":"657_CR4","first-page":"47","volume":"6","author":"D Ferreira","year":"2014","unstructured":"Ferreira D, et al. Meta-review of CSF core biomarkers in Alzheimer\u2019s disease: the state-of-the-art after the new revised diagnostic criteria. Front Aging Neurosci. 2014;6:47.","journal-title":"Front Aging Neurosci"},{"issue":"7266","key":"657_CR5","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/nature08538","volume":"461","author":"RJ Perrin","year":"2009","unstructured":"Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer\u2019s disease. Nature. 2009;461(7266):916\u201322.","journal-title":"Nature"},{"issue":"1","key":"657_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JAD-2009-1124","volume":"18","author":"B Zhou","year":"2009","unstructured":"Zhou B, et al. Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer's disease. J Alzheimers Dis. 2009;18(1):89\u2013102.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"657_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack CR Jr, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9(1):119\u201328.","journal-title":"Lancet Neurol"},{"issue":"12","key":"657_CR8","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40263-017-0483-3","volume":"31","author":"A Ardura-Fabregat","year":"2017","unstructured":"Ardura-Fabregat A, et al. Targeting neuroinflammation to treat Alzheimer\u2019s disease. CNS Drugs. 2017;31(12):1057\u201382.","journal-title":"CNS Drugs"},{"issue":"6","key":"657_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P. Neuroinflammation in Alzheimer\u2019s disease: current evidence and future directions. Alzheimers Dement. 2016;12(6):719\u201332.","journal-title":"Alzheimers Dement"},{"key":"657_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.expneurol.2012.10.007","volume":"239","author":"R Medeiros","year":"2013","unstructured":"Medeiros R, LaFerla FM. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol. 2013;239:133\u20138.","journal-title":"Exp Neurol"},{"issue":"12","key":"657_CR11","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1084\/jem.20021546","volume":"197","author":"JB El Khoury","year":"2003","unstructured":"El Khoury JB, et al. CD36 mediates the innate host response to beta-amyloid. J Exp Med. 2003;197(12):1657\u201366.","journal-title":"J Exp Med"},{"key":"657_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fnins.2015.00259","volume":"9","author":"L Steardo Jr","year":"2015","unstructured":"Steardo L Jr, et al. Does neuroinflammation turn on the flame in Alzheimer\u2019s disease? Focus on astrocytes. Front Neurosci. 2015;9:259.","journal-title":"Front Neurosci"},{"issue":"6","key":"657_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358\u201372.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"657_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.molmed.2018.11.006","volume":"25","author":"SF Carter","year":"2019","unstructured":"Carter SF, et al. Astrocyte biomarkers in Alzheimer\u2019s disease. Trends Mol Med. 2019;25(2):77\u201395.","journal-title":"Trends Mol Med"},{"issue":"4","key":"657_CR15","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1750-3639.2011.00550.x","volume":"22","author":"D Bonneh-Barkay","year":"2012","unstructured":"Bonneh-Barkay D, et al. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain pathology (Zurich). 2012;22(4):530\u201346.","journal-title":"Brain pathology (Zurich)"},{"issue":"6","key":"657_CR16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.bbamcr.2008.11.009","volume":"1793","author":"R Donato","year":"2009","unstructured":"Donato R, et al. S100B's double life: intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009;1793(6):1008\u201322.","journal-title":"Biochim Biophys Acta"},{"issue":"6","key":"657_CR17","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tins.2015.04.003","volume":"38","author":"Z Yang","year":"2015","unstructured":"Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364\u201374.","journal-title":"Trends Neurosci"},{"issue":"45","key":"657_CR18","doi-asserted-by":"publisher","first-page":"44058","DOI":"10.1074\/jbc.M306792200","volume":"278","author":"M Rehli","year":"2003","unstructured":"Rehli M, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem. 2003;278(45):44058\u201367.","journal-title":"J Biol Chem"},{"issue":"10","key":"657_CR19","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol Psychiatry. 2010;68(10):903\u201312.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"657_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12974-017-0893-7","volume":"14","author":"M Querol-Vilaseca","year":"2017","unstructured":"Querol-Vilaseca M, et al. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer\u2019s disease and other tauopathies. J Neuroinflammation. 2017;14(1):118.","journal-title":"J Neuroinflammation"},{"issue":"19","key":"657_CR21","doi-asserted-by":"publisher","first-page":"7611","DOI":"10.1073\/pnas.86.19.7611","volume":"86","author":"WS Griffin","year":"1989","unstructured":"Griffin WS, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A. 1989;86(19):7611\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"657_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/00005072-199603000-00002","volume":"55","author":"RE Mrak","year":"1996","unstructured":"Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer\u2019s disease. J Neuropathol Exp Neurol. 1996;55(3):273\u20139.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"657_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/5225","volume":"17","author":"DK Hanzel","year":"1999","unstructured":"Hanzel DK, et al. High-throughput quantitative histological analysis of Alzheimer\u2019s disease pathology using a confocal digital microscanner. Nat Biotechnol. 1999;17(1):53\u20137.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"657_CR24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1440-1819.1998.tb02706.x","volume":"52","author":"F Muramori","year":"1998","unstructured":"Muramori F, Kobayashi K, Nakamura I. A quantitative study of neurofibrillary tangles, senile plaques and astrocytes in the hippocampal subdivisions and entorhinal cortex in Alzheimer\u2019s disease, normal controls and non-Alzheimer neuropsychiatric diseases. Psychiatry Clin Neurosci. 1998;52(6):593\u20139.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"2","key":"657_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0197-4580(02)00090-8","volume":"24","author":"AK Vehmas","year":"2003","unstructured":"Vehmas AK, et al. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging. 2003;24(2):321\u201331.","journal-title":"Neurobiol Aging"},{"issue":"7","key":"657_CR26","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673\u201384.","journal-title":"Lancet Neurol"},{"issue":"6","key":"657_CR27","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.neurobiolaging.2015.03.001","volume":"36","author":"D Alcolea","year":"2015","unstructured":"Alcolea D, et al. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer\u2019s disease. Neurobiol Aging. 2015;36(6):2018\u201323.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"657_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JAD-140240","volume":"42","author":"D Alcolea","year":"2014","unstructured":"Alcolea D, et al. Relationship between beta-Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer\u2019s disease. J Alzheimers Dis. 2014;42(1):157\u201367.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"657_CR29","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3233\/JAD-140624","volume":"42","author":"A Antonell","year":"2014","unstructured":"Antonell A, et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer\u2019s disease. J Alzheimers Dis. 2014;42(3):901\u20138.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"657_CR30","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3233\/JAD-150897","volume":"50","author":"KE Melah","year":"2016","unstructured":"Melah KE, et al. Cerebrospinal fluid markers of Alzheimer\u2019s disease pathology and microglial activation are associated with altered white matter microstructure in asymptomatic adults at risk for Alzheimer\u2019s disease. J Alzheimers Dis. 2016;50(3):873\u201386.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"657_CR31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746","volume":"76","author":"B Olsson","year":"2019","unstructured":"Olsson B, et al. Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol. 2019;76(3):318\u201325.","journal-title":"JAMA Neurol"},{"issue":"3","key":"657_CR32","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1159\/000481853","volume":"7","author":"KR Hov","year":"2017","unstructured":"Hov KR, et al. Cerebrospinal fluid S100B and Alzheimer\u2019s disease biomarkers in hip fracture patients with delirium. Dement Geriatr Cogn Dis Extra. 2017;7(3):374\u201385.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"2","key":"657_CR33","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jnc.13399","volume":"136","author":"A Ishiki","year":"2016","unstructured":"Ishiki A, et al. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer\u2019s disease, dementia with Lewy bodies, and frontotemporal lobar degeneration. J Neurochem. 2016;136(2):258\u201361.","journal-title":"J Neurochem"},{"issue":"10","key":"657_CR34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrn3085","volume":"12","author":"SA Small","year":"2011","unstructured":"Small SA, et al. A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci. 2011;12(10):585\u2013601.","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"657_CR35","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S0010-9452(08)70683-X","volume":"43","author":"JS Snowden","year":"2007","unstructured":"Snowden JS, et al. Cognitive phenotypes in Alzheimer\u2019s disease and genetic risk. Cortex. 2007;43(7):835\u201345.","journal-title":"Cortex"},{"issue":"6","key":"657_CR36","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614\u201329.","journal-title":"Lancet Neurol"},{"issue":"1","key":"657_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1017\/S003329170002691X","volume":"24","author":"AF Jorm","year":"1994","unstructured":"Jorm AF. A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol Med. 1994;24(1):145\u201353.","journal-title":"Psychol Med"},{"issue":"3","key":"657_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7(3):263\u20139.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"657_CR39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"3","key":"657_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","volume":"256","author":"B Winblad","year":"2004","unstructured":"Winblad B, et al. Mild cognitive impairment \u2013 beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240\u20136.","journal-title":"J Intern Med"},{"issue":"6","key":"657_CR41","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jalz.2013.12.023","volume":"10","author":"FH Duits","year":"2014","unstructured":"Duits FH, et al. The cerebrospinal fluid \u201cAlzheimer profile\u201d: easily said, but what does it mean? Alzheimers Dement. 2014;10(6):713\u2013723.e2.","journal-title":"Alzheimers Dement"},{"key":"657_CR42","volume-title":"Neuropsychological assessment","author":"MD Lezak","year":"2012","unstructured":"Lezak MD. Neuropsychological assessment. Oxford: Oxford University Press; 2012."},{"key":"657_CR43","volume-title":"WMS-R : Wechsler Memory Scale-Revised : manual","author":"D Wechsler","year":"1987","unstructured":"Wechsler D. WMS-R : Wechsler Memory Scale-Revised : manual. San Antonio: Harcourt Brace Jovanovich; 1987."},{"key":"657_CR44","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3389\/fpsyg.2014.00772","volume":"5","author":"Z Shao","year":"2014","unstructured":"Shao Z, et al. What do verbal fluency tasks measure? Predictors of verbal fluency performance in older adults. Front Psychol. 2014;5:772.","journal-title":"Front Psychol"},{"issue":"2","key":"657_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0887-6177(03)00039-8","volume":"19","author":"TN Tombaugh","year":"2004","unstructured":"Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19(2):203\u201314.","journal-title":"Arch Clin Neuropsychol"},{"issue":"6","key":"657_CR46","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1037\/h0054651","volume":"18","author":"JR Stroop","year":"1935","unstructured":"Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643\u201362.","journal-title":"J Exp Psychol"},{"key":"657_CR47","first-page":"498","volume-title":"Wechsler adult intelligence scale\u2013Fourth Edition (WAIS\u2013IV)","author":"D Wechsler","year":"2008","unstructured":"Wechsler D. Wechsler adult intelligence scale\u2013Fourth Edition (WAIS\u2013IV), vol. 22. San Antonio: NCS Pearson; 2008. p. 498."},{"issue":"3","key":"657_CR48","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837\u201345.","journal-title":"Biometrics"},{"issue":"1","key":"657_CR49","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani R. Regression shrinkage and selection via the lasso. J Royal Stat Soc Series B (Methodological). 1996;58(1):267\u201388.","journal-title":"J Royal Stat Soc Series B (Methodological)"},{"issue":"1","key":"657_CR50","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12859-015-0575-3","volume":"16","author":"B Hofner","year":"2015","unstructured":"Hofner B, Boccuto L, G\u00f6ker M. Controlling false discoveries in high-dimensional situations: boosting with stability selection. BMC Bioinformatics. 2015;16(1):144.","journal-title":"BMC Bioinformatics"},{"issue":"4","key":"657_CR51","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1467-9868.2010.00740.x","volume":"72","author":"N Meinshausen","year":"2010","unstructured":"Meinshausen N, B\u00fchlmann P. Stability selection. J Royal Stat Soc: Series B (Statistical Methodology). 2010;72(4):417\u201373.","journal-title":"J Royal Stat Soc: Series B (Statistical Methodology)"},{"key":"657_CR52","doi-asserted-by":"crossref","unstructured":"Consensus report of the Working Group on: Molecular and biochemical markers of Alzheimer\u2019s disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer\u2019s Association and the National Institute on Aging Working Group. Neurobiol Aging, 1998. 19(2): p. 109\u2013116.","DOI":"10.1016\/S0197-4580(98)00022-0"},{"issue":"1","key":"657_CR53","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/13607860903071014","volume":"14","author":"M Ganguli","year":"2010","unstructured":"Ganguli M, et al. Age and education effects and norms on a cognitive test battery from a population-based cohort: the Monongahela-Youghiogheny Healthy Aging Team. Aging Ment Health. 2010;14(1):100\u20137.","journal-title":"Aging Ment Health"},{"issue":"7","key":"657_CR54","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1212\/WNL.0000000000001859","volume":"85","author":"D Alcolea","year":"2015","unstructured":"Alcolea D, et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology. 2015;85(7):626\u201333.","journal-title":"Neurology"},{"issue":"10","key":"657_CR55","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.15252\/emmm.201606540","volume":"8","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, et al. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer\u2019s disease. EMBO Mol Med. 2016;8(10):1184\u201396.","journal-title":"EMBO Mol Med"},{"key":"657_CR56","doi-asserted-by":"crossref","unstructured":"Olsson, B., et al., Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol. 2019;76(3):318\u201325.","DOI":"10.1001\/jamaneurol.2018.3746"},{"issue":"1","key":"657_CR57","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13195-018-0426-3","volume":"10","author":"U Gangishetti","year":"2018","unstructured":"Gangishetti U, et al. Non-beta-amyloid\/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther. 2018;10(1):98.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"657_CR58","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-015-0142-1","volume":"7","author":"MI Kester","year":"2015","unstructured":"Kester MI, et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer\u2019s disease in a memory clinic cohort. Alzheimers Res Ther. 2015;7(1):59.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"657_CR59","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s11065-017-9360-6","volume":"27","author":"GH Weissberger","year":"2017","unstructured":"Weissberger GH, et al. Diagnostic accuracy of memory measures in Alzheimer\u2019s dementia and mild cognitive impairment: a systematic review and meta-analysis. Neuropsychol Rev. 2017;27(4):354\u201388.","journal-title":"Neuropsychol Rev"},{"issue":"1","key":"657_CR60","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","volume":"73","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H, et al. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA neurology. 2016;73(1):60\u20137.","journal-title":"JAMA neurology"},{"key":"657_CR61","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.exger.2015.11.008","volume":"73","author":"M Guhra","year":"2016","unstructured":"Guhra M, et al. Linking CSF and cognition in Alzheimer\u2019s disease: reanalysis of clinical data. Exp Gerontol. 2016;73:107\u201313.","journal-title":"Exp Gerontol"},{"issue":"4","key":"657_CR62","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1017\/S135561770808079X","volume":"14","author":"A Nordlund","year":"2008","unstructured":"Nordlund A, et al. Episodic memory and speed\/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI. J Int Neuropsychol Soc. 2008;14(4):582\u201390.","journal-title":"J Int Neuropsychol Soc"},{"issue":"1","key":"657_CR63","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JAD-2011-110038","volume":"26","author":"S Rolstad","year":"2011","unstructured":"Rolstad S, et al. Amyloid-beta(4)(2) is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J Alzheimers Dis. 2011;26(1):135\u201342.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"657_CR64","doi-asserted-by":"publisher","first-page":"e37720","DOI":"10.1371\/journal.pone.0037720","volume":"7","author":"BB Bendlin","year":"2012","unstructured":"Bendlin BB, et al. CSF T-Tau\/Abeta42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease. PLoS One. 2012;7(6):e37720.","journal-title":"PLoS One"},{"issue":"5","key":"657_CR65","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jalz.2014.05.1754","volume":"11","author":"D Bertens","year":"2015","unstructured":"Bertens D, et al. Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer\u2019s disease. Alzheimers Dement. 2015;11(5):511\u201322.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"657_CR66","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1016\/j.neurobiolaging.2013.04.027","volume":"34","author":"T Darreh-Shori","year":"2013","unstructured":"Darreh-Shori T, et al. Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer\u2019s disease. Neurobiol Aging. 2013;34(11):2465\u201381.","journal-title":"Neurobiol Aging"},{"issue":"3","key":"657_CR67","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3233\/JAD-161146","volume":"58","author":"R Sala-Llonch","year":"2017","unstructured":"Sala-Llonch R, et al. Inflammation, amyloid, and atrophy in the aging brain: relationships with longitudinal changes in cognition. J Alzheimers Dis. 2017;58(3):829\u201340.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"657_CR68","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jalz.2019.01.004","volume":"15","author":"I Bos","year":"2019","unstructured":"Bos I, et al. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer\u2019s disease spectrum. Alzheimers Dement. 2019;15(5):644\u201354.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"657_CR69","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamaneurol.2015.1285","volume":"72","author":"CL Sutphen","year":"2015","unstructured":"Sutphen CL, et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol. 2015;72(9):1029\u201342.","journal-title":"JAMA Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00657-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-020-00657-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00657-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T16:37:42Z","timestamp":1650213462000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00657-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00657-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.19886\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.19886\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,4]]},"assertion":[{"value":"26 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study has been approved by the National Research Ethics Committee of Iceland (VSN-14-028), and all subjects signed an informed consent. The study was conducted in accordance with the Helsinki Declaration latest revision of 2013.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}